市場調査レポート

商品コード

1566192

オンコロジーの市場規模、シェア、成長分析、がん診断・治療別、がんタイプ別、最終用途別、地域別 - 産業予測、2024年～2031年

Oncology Market Size, Share, Growth Analysis, By Cancer Diagnostics & Treatment, By Cancer Type, By End Use, By Region - Industry Forecast 2024-2031

出版日: 2024年10月01日 | 発行: SkyQuest

| ページ情報: 英文 157 Pages | 納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 799,505円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 935,270円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,071,035円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=150.85円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界のオンコロジーの市場規模は、2022年に約2,018億米ドルと評価され、2023年の2,244億米ドルから上昇し、予測期間（2024-2031年）のCAGRは11.2%で、2031年には4,718億米ドルに達すると予測されています。

がんは、心血管系疾患、寄生虫疾患、感染症に次いで、世界で3番目に致死率の高い疾患です。その結果、オンコロジー市場は、効果的な治療ソリューションに対する緊急のニーズによって大きな成長を遂げています。発がんを抑制するために合成または天然に存在する化学物質を使用する化学予防は、ますます重要性を増しています。現在のがん治療手法には、手術、放射線療法、薬理学的介入があります。手術は依然として早期がんに対する主要な治療法であり、放射線療法は限局した腫瘍に対しては手術と並行して行われることが多いです。さらに、薬物療法、特に様々な細胞毒性薬剤を使用する化学療法は、管理戦略において重要な役割を果たしています。がん細胞の増殖や転移を促進する特定の遺伝子変化に対処する標的療法は、有望な治療法として注目を集めています。アルコールとタバコの消費量の増加によるがんの有病率の上昇は、革新的な解決策の緊急性を強調しています。その結果、業界各社は多様な悪性腫瘍に対処することを目的とした新規治療薬候補の開発に多額の投資を行っています。このような研究開発への注力は、利害関係者が治療薬の進歩を求め続けていることから、予測期間を通じて治療成績を向上させ、市場の成長を促進するものと思われます。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

Roche Holding AG
Novartis International AG
Pfizer Inc.
Bristol-Myers Squibb Company
Merck & Co., Inc.
AstraZeneca plc
Johnson & Johnson（Janssen Pharmaceuticals）
Eli Lilly and Company
Amgen Inc.
Sanofi S.A.
Bayer AG
Takeda Pharmaceutical Company
AbbVie Inc.
Gilead Sciences, Inc.
Astellas Pharma Inc.
Celgene Corporation（acquired by Bristol-Myers Squibb）
Regeneron Pharmaceuticals, Inc.
GlaxoSmithKline plc（GSK）
Daiichi Sankyo Company, Limited
Seagen Inc.

Product Code: SQSG35J2013

Global Oncology Market size was valued at around USD 201.8 billion in 2022 and is expected to rise from USD 224.4 billion in 2023 to reach a value of USD 471.8 billion by 2031, at a CAGR of 11.2% over the forecast period (2024-2031).

Cancer ranks as the third most lethal disease globally, trailing only behind cardiovascular, parasitic, and infectious diseases. As a result, the market for oncology is experiencing significant growth driven by the urgent need for effective treatment solutions. Chemoprevention, which involves using synthetic or naturally occurring chemicals to inhibit carcinogenesis, is becoming increasingly relevant. Current cancer treatment methodologies encompass surgery, radiation therapy, and pharmacological interventions. Surgery remains the primary treatment choice for early-stage cancer, while radiotherapy is often employed alongside surgical procedures for localized tumors. Additionally, pharmacotherapy, particularly chemotherapy that utilizes a variety of cytotoxic agents, plays a crucial role in management strategies. Targeted therapy, which addresses specific genetic alterations in cancer cells that promote their growth and metastasis, is gaining traction as a promising treatment avenue. The escalating prevalence of cancer due to rising alcohol and tobacco consumption underscores the urgency for innovative solutions. Consequently, industry players are heavily investing in the development of novel therapeutic candidates aimed at addressing the diverse spectrum of malignancies. This focus on research and development is poised to enhance treatment outcomes and propel market growth throughout the forecast period, as stakeholders continue to seek advancements in oncology therapeutics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Oncology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Oncology Market Segmental Analysis

Global Oncology Market is segmented by Cancer Diagnostics & Treatment, Cancer Type, End Use, and region. Based on Cancer Diagnostics & Treatment, the market is segmented into Cancer Diagnostics (Tumor Biomarker Test, Imaging, Biopsy, Liquid Biopsy, Immunohistochemistry, In Situ Hybridization), Cancer Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy). Based on Cancer Type, the market is segmented into Lung Cancer, Prostate Cancer, Colon & Rectal Cancer, Gastric Cancer, Esophageal Cancer, Liver Cancer, and Breast Cancer. Based on End Use, the market is segmented into Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, Academia, Specialty Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Oncology Market

The global oncology market is poised for significant growth, primarily driven by the alarming rise in cancer prevalence worldwide, currently the second leading cause of death after cardiovascular diseases. Factors such as tobacco use, shifting dietary habits, and an increase in life expectancy contribute to this surge, with the World Health Organization projecting new cancer cases to skyrocket from 18.1 million in 2018 to an anticipated 29.4 million by 2040. This escalating burden necessitates effective oncology medications, thereby bolstering market demand. Furthermore, heightened public awareness of cancer risks and treatment options is expected to further stimulate market expansion in the coming years.

Restraints in the Global Oncology Market

The global oncology market faces several significant restraints that hinder its growth trajectory. Adverse drug effects associated with chemotherapy, such as bone marrow suppression, gastrointestinal disorders, neuropathies, and hair loss, not only compromise patient quality of life but also lead to treatment discontinuation, thereby limiting market expansion. Additionally, stringent regulatory frameworks governing drug approvals and high medication costs pose significant barriers for pharmaceutical companies. Furthermore, the impending patent expirations of key oncology drugs introduce competitive pressures, causing a decline in revenue for innovators and stalling investment in new therapies. Collectively, these factors present formidable challenges to the market's progress in the coming years.

Market Trends of the Global Oncology Market

The Global Oncology market is witnessing a robust trend of expansion, driven by an intensified focus on research and development (R&D) for advanced drug therapies, particularly in immunotherapy. As cancer treatment increasingly prioritizes curing the disease, prolonging survival, and enhancing patients' quality of life, market leaders are channeling significant investments into immunotherapy research. The collaboration between companies like FUJIFILM Corporation and the National Cancer Center Japan highlights a growing emphasis on innovative treatments that leverage immune cells to combat tumors. This strategic shift towards effective immunotherapeutic solutions is not only improving patient outcomes but also propelling substantial growth within the oncology sector.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Regulatory Analysis
Case Study Analysis
Technology Analysis
Pricing Analysis
Clinical Trials

Oncology Market, By Cancer Diagnostics & Treatment

Market Overview
Cancer Diagnostics
- Biopsy
- Imaging
- Immunohistochemistry
- Tumor Biomarkers Test
- In Situ Hybridization
- Liquid Biopsy
Cancer Treatment
- Targeted Therapy
- Chemotherapy
- Hormonal Therapy
- Immunotherapy
- Others

Oncology Market, By Indication

Market Overview
Lungs Cancer
Colorectal Cancer
Breast Cancer
Liver Cancer
Bladder Cancer
Head & Neck Cancer
Prostate Cancer
Others

Oncology Market, By End Use

Market Overview
Hospitals
Diagnostic laboratories
Diagnostic imaging centers
Academia
Specialty clinics
Others

Oncology Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Roche Holding AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (Janssen Pharmaceuticals)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (acquired by Bristol-Myers Squibb)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (GSK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seagen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

オンコロジーの市場規模、シェア、成長分析、がん診断・治療別、がんタイプ別、最終用途別、地域別 - 産業予測、2024年～2031年

Oncology Market Size, Share, Growth Analysis, By Cancer Diagnostics & Treatment, By Cancer Type, By End Use, By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

オンコロジー市場：がん診断・治療別

オンコロジー市場：市場：適応症別

オンコロジー市場：最終用途別

オンコロジー市場規模：地域別